Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
Phase 3negativeNegative
AI Analysis
Summary
Ultragenyx announced a Phase 3 trial failure for its Angelman syndrome drug candidate, resulting in a stock price decline. The negative trial outcome represents a significant setback for the company's pipeline.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Importance:8/10
Sentiment:
-0.90
Phase_3_failureAngelman_syndromeclinical_trialnegative_catalyst
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on September 3, 2026 5:55 AM